IN2009DN05758A - - Google Patents

Download PDF

Info

Publication number
IN2009DN05758A
IN2009DN05758A IN5758DEN2009A IN2009DN05758A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A IN 5758DEN2009 A IN5758DEN2009 A IN 5758DEN2009A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A
Authority
IN
India
Prior art keywords
antibodies
solubility
methods
stability
scfv
Prior art date
Application number
Inventor
Urech David
Borras Leonardo
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Ag filed Critical Esbatech Ag
Publication of IN2009DN05758A publication Critical patent/IN2009DN05758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.
IN5758DEN2009 2007-03-12 2008-03-12 IN2009DN05758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90636507P 2007-03-12 2007-03-12
PCT/EP2008/001958 WO2008110348A1 (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
IN2009DN05758A true IN2009DN05758A (en) 2015-07-24

Family

ID=39586970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5758DEN2009 IN2009DN05758A (en) 2007-03-12 2008-03-12

Country Status (12)

Country Link
US (2) US8280711B2 (en)
EP (2) EP2118138A1 (en)
JP (1) JP5622397B2 (en)
CN (2) CN103275216B (en)
AU (1) AU2008226067B2 (en)
CA (1) CA2680564C (en)
HK (1) HK1138602A1 (en)
IL (1) IL200710A (en)
IN (1) IN2009DN05758A (en)
NZ (1) NZ579594A (en)
RU (2) RU2009137582A (en)
WO (1) WO2008110348A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
EP2164961B1 (en) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
DK3241843T3 (en) 2008-06-25 2021-09-06 Novartis Ag Solubility optimization of immune binders
KR102007492B1 (en) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 Humanization of rabbit antibodies using a universal antibody framework
PL3216803T3 (en) 2008-06-25 2020-10-19 Novartis Ag Stable and soluble antibodies inhibiting vegf
HUE039692T2 (en) 2008-06-25 2019-01-28 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting tnf
MX347291B (en) 2009-03-20 2017-04-17 Amgen Inc Carrier immunoglobulins and uses thereof.
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
EA201370076A1 (en) 2010-09-22 2013-08-30 Амген Инк. IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
AR083495A1 (en) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit STABLE AND SOLUBLE ANTIBODIES
GB201310859D0 (en) * 2013-06-18 2013-07-31 Cambridge Entpr Ltd Rational method for solubilising proteins
KR20160052562A (en) * 2013-09-06 2016-05-12 에프. 호프만-라 로슈 아게 Method for improving antibody stability
AR101875A1 (en) 2014-09-15 2017-01-18 Amgen Inc ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME
JP6932700B2 (en) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド Tetravalent bispecific antigen-binding proteins and tetravalent quadrispecific antigen-binding proteins, and their use
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
EP3538555A1 (en) 2016-11-14 2019-09-18 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
JP2021525779A (en) * 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ， インク． Universal or normalized antibody framework for improving functionality and manufacturability
TW202110877A (en) 2019-05-30 2021-03-16 美商安進公司 Engineering the hinge region to drive antibody dimerization
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
UY38995A (en) 2019-12-20 2021-06-30 Amgen Inc MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
WO2022040466A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP2023544769A (en) 2020-10-07 2023-10-25 アムジエン・インコーポレーテツド Rational selection of building blocks for the construction of multispecific antibodies
AU2021379598A1 (en) 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN116848136A (en) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 Complement C3 antigen binding proteins
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
JP2024515301A (en) 2021-04-20 2024-04-08 アムジエン・インコーポレーテツド Balanced charge distribution in electrostatic steering of chain pairing in the association of multispecific and monovalent IGG molecules
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
DK0929578T3 (en) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Human antibodies that bind human TNFalfa
CN1062312C (en) * 1996-11-29 2001-02-21 中国科学院微生物研究所 Type 1V collagenase-resisting single stranded antibody
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
CN1689646A (en) 1998-08-11 2005-11-02 拜奥根Idec公司 Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69918717T2 (en) 1998-12-14 2005-07-21 Osteotech, Inc. BONE TRANSPLANT FROM BONE PARTICLES
CN1232039A (en) * 1999-04-02 1999-10-20 中国人民解放军海军总医院 Genetic engineering double specific antibody and its use
SE9901379D0 (en) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
ATE273323T1 (en) * 1999-12-28 2004-08-15 Esbatech Ag INTRABODY WITH DEFINED STRUCTURE (ßFRAMEWORKß) STABLE IN A REDUCING ENVIRONMENT AND THEIR USES
ATE536375T1 (en) 2000-05-10 2011-12-15 Mayo Foundation HUMAN IGM ANTIBODIES WHICH HAVE THE ABILITY TO INDUCE THE RECONSTRUCTION OF MYELIN STRUCTURE AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS IN THE CENTRAL NERVOUS SYSTEM
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
WO2003008451A2 (en) * 2001-07-19 2003-01-30 Universität Zürich Modification of human variable domains
AU2003238370B2 (en) 2002-05-22 2010-04-29 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
GB2408508A (en) 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
KR20070084170A (en) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CN102924597A (en) 2005-06-07 2013-02-13 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Stable and soluble antibodies inhibiting TNFa
RS57255B1 (en) 2005-12-13 2018-08-31 Lilly Co Eli Anti-il-17 antibodies
SI2046382T1 (en) 2006-07-10 2016-12-30 ESBATech an Alcon Biomedical Research Unit LLC scFv ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies

Also Published As

Publication number Publication date
JP2010523077A (en) 2010-07-15
AU2008226067B2 (en) 2012-11-08
CN101668771A (en) 2010-03-10
CA2680564A1 (en) 2008-09-18
JP5622397B2 (en) 2014-11-12
EP3202786A2 (en) 2017-08-09
AU2008226067A1 (en) 2008-09-18
CN103275216B (en) 2015-05-06
US20100137150A1 (en) 2010-06-03
WO2008110348A1 (en) 2008-09-18
EP2118138A1 (en) 2009-11-18
IL200710A (en) 2014-07-31
CN103275216A (en) 2013-09-04
US20130053259A1 (en) 2013-02-28
RU2014127308A (en) 2016-02-10
NZ579594A (en) 2012-03-30
IL200710A0 (en) 2010-05-17
US9938336B2 (en) 2018-04-10
US8280711B2 (en) 2012-10-02
HK1138602A1 (en) 2010-08-27
RU2009137582A (en) 2011-04-20
EP3202786A3 (en) 2017-10-11
CN101668771B (en) 2013-08-21
CA2680564C (en) 2018-05-01

Similar Documents

Publication Publication Date Title
IN2009DN05758A (en)
MX2009013327A (en) Sequence based engineering and optimization of single chain antibodies.
MX2009013328A (en) Methods of modifying antibodies, and modified antibodies with improved functional properties.
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
AR083747A1 (en) ANTI-IL-23 ANTIBODIES
UA99701C2 (en) Human monoclonal antibody that specifically binds to programmed death ligand 1 (pd-l1)
IN2014MN00873A (en)
ECSP11011239A (en) IL-1 BINDING PROTEINS
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
TN2014000120A1 (en) Cd27l antigen binding proteins
MX342413B (en) Antibodies to matrix metalloproteinase 9.
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
DE602005027399D1 (en) FOR HUMAN MATRIPTASE SPECIFIC TIE PROTEINS
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
ATE431423T1 (en) METHOD FOR SCREENING THE LIGHT CHAIN OF AN ANTIBODY
MX2010006767A (en) Hepatitis c virus antibodies.
NO20092285L (en) Human monoclonal antibodies to BTLA and methods of use
UA94576C2 (en) Isolated antibody that binds to igf-1r, composition and methods relating to anti-igf-1 receptor antibodies
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
MXPA06010715A (en) Human anti-epidermal growth factor receptor antibody.
UA106070C2 (en) Antibody that specifically binds to egfr and her3
NO20054351L (en) Monoclonal antibody and hybridoma producing this
CO6410312A2 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN OX40